CDC- BRFSS – ACBS 2024 Adult Prevalence Table 8

Table 8: Estimated percent using inhaled short acting beta agonists among adults1 with current2 asthma status by state/territory – BRFSS Asthma Call-back Survey, United States, 2024.
State/Territory Current
Sample
size±
% SE§ 95% CI
Arizona 328 51.8 4.9 (42.2 – 61.4)
California 273 48.8 4.9 (39.2 – 58.4)
Connecticut 301 53.7 3.9 (46.1 – 61.3)
Florida 365 53.5 4.9 (43.9 – 63.1)
Georgia 324 52.5 4.0 (44.7 – 60.3)
Illinois 344 53.5 3.5 (46.6 – 60.4)
Indiana 573 57.2 2.5 (52.3 – 62.1)
Iowa 265 52.9 4.2 (44.7 – 61.1)
Kansas 312 51.2 3.8 (43.8 – 58.6)
Kentucky 146 51.7 5.4 (41.1 – 62.3)
Maine 412 59.6 3.4 (52.9 – 66.3)
Maryland 639 51.3 3.0 (45.4 – 57.2)
Massachusetts 355 52.7 3.5 (45.8 – 59.6)
Michigan 502 50.0 3.3 (43.5 – 56.5)
Minnesota 655 47.5 2.5 (42.6 – 52.4)
Missouri 171 65.9 5.5 (55.1 – 76.7)
Nebraska 326 53.4 4.4 (44.8 – 62.0)
New Hampshire 333 57.5 4.1 (49.5 – 65.5)
New Jersey 380 50.2 3.7 (42.9 – 57.5)
New York 821 52.0 2.6 (46.9 – 57.1)
Ohio 371 50.8 3.8 (43.4 – 58.2)
Oregon 201 55.4 4.3 (47.0 – 63.8)
Rhode Island 239 52.9 4.4 (44.3 – 61.5)
Texas 219 56.4 5.5 (45.6 – 67.2)
Utah 484 54.8 3.2 (48.5 – 61.1)
Vermont 310 52.8 3.8 (45.4 – 60.2)
Wisconsin 425 50.1 3.5 (43.2 – 57.0)
Puerto Rico 222 37.5 4.3 (29.1 – 45.9)
28 States / Area 10,296 52.4 1.1 (50.2 – 54.6)
Median 52.8
Range 37.5-65.9

 

1 Aged ≥ 18 years

2 “Yes” response to “Do you still have asthma?”

± Sample size for adults with current asthma, excludes “DK/Refused”

§ Standard error

Confidence interval

Link for Summary Data Quality Report: https://www.cdc.gov/brfss/acbs/2024/pdf/sdq_report_acbs_24-508.pdf